Impact of Daily Prophylaxis Dose Anticoagulation With a Factor Xa Inhibitor (Apixaban) in Patients With Sickle Cell Disease
Phase of Trial: Phase III
Latest Information Update: 24 Apr 2019
Price : $35 *
At a glance
- Drugs Apixaban (Primary)
- Indications Sickle cell anaemia; Venous thromboembolism
- Focus Therapeutic Use
- 15 Apr 2019 Status changed from recruiting to discontinued.
- 15 Nov 2018 Planned number of patients changed to 25.
- 15 Nov 2018 Planned End Date changed to 30 Sep 2019.